

Freedom of Information Request	FOI 21-122	12 th April 2021
--------------------------------	------------	-----------------------------

Q1. How many patients have been treated in the last 6 months for Urinary Tract Infections (ICD10 code N39.0) with the following:

- **Ceftazidime/avibactam (Zavicefta)** 30 vials
- **Ceftolozane/tazobactam (Zerbaxa)** Nil
- **Meropenem/vaborbactam (Vaborem)** Nil
- **Cefiderocol (Fetcroja)** Nil
- **Meropenem:** 1g vials: 11, 422 vials
Meropenem: 500mg vials: 2424 vials

Q2. How many patients have been treated in the last 6 months for Post-procedural Respiratory Disorders (ICD10 code J95.8) with the following:

- **Ceftazidime/avibactam (Zavicefta)**
- **Ceftolozane/tazobactam (Zerbaxa)**
- **Meropenem/vaborbactam (Vaborem)**
- **Cefiderocol (Fetcroja)**
- **Meropenem**

Please refer to Q1

Q3. How many patients have been treated in the last 6 months for Hospital Acquired Pneumonia (ICD10 codes J15 and Y95 in the same inpatient spell) with the following:

- **Ceftazidime/avibactam (Zavicefta)**
- **Ceftolozane/tazobactam (Zerbaxa)**
- **Meropenem/vaborbactam (Vaborem)**
- **Cefiderocol (Fetcroja)**
- **Meropenem**

Please refer to Q1

Q4. How many patients who underwent a laparotomy/laparoscopic approach to the abdominal cavity (any one of OPCS codes Y502, Y751, Y752 or Y755) in the last 6 months, were treated with the following:

- **Ceftazidime/avibactam (Zavicefta)**
- **Ceftolozane/tazobactam (Zerbaxa)**
- **Meropenem/vaborbactam (Vaborem)**
- **Cefiderocol (Fetcroja)**
- **Meropenem**

Please refer to Q1